Page 282 - Haematologica May 2020

A. Delluc et al.
12. Nyaga VN, Arbyn M, Aerts M. Metaprop: a
Stata command to perform meta-analysis of binomial data. Archives of public health = Archives belges de sante publique. 2014; 72(1):39.
13. Astruc N, Ianotto JC, Metges JP, Lacut K, Delluc A. External validation of the modi- fied Ottawa score for risk stratification of recurrent cancer-associated thrombosis. Eur J Intern Med. 2016;36:e11-e12.
14. Louzada ML, Bose G, Cheung A, Chin-Yee BH, Wells S, Wells PS. Predicting Venous Thromboembolism Recurrence Risk in Patients with Cancer: A Validation Study. Blood. 2012;120(21):394-394.
15. van Es N, Louzada M, Carrier M, et al. Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study. Thromb Res. 2018;163:41-46.
16. Alatri A, Mazzolai L, Font C, et al. Low dis- criminating power of the modified Ottawa VTE risk score in a cohort of patients with cancer from the RIETE registry. Thromb Haemost. 2017;117(8):1630-1636.
17. den Exter PL, Kooiman J, Huisman MV. Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer- associated thrombosis. J Thromb Haemost. 2013;11(5):998-1000.
18. Khorana AA, Kamphuisen PW, Meyer G, et al. Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial. J Clin Oncol. 2017;35(10):1078-1085.
19. Ahn S, Lim KS, Lee YS, Lee JL. Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2013;21(8):2309-2313.
20. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125(1):1-7.
21. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;
369(9):799-808.
22. Büller HR, Prins MH, Lensin AWA, et al.
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297.
23. Lloyd AJ, Dewilde S, Noble S, Reimer E, Lee AYY. What Impact Does Venous Thromboembolism and Bleeding Have on Cancer Patients' Quality of Life? Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018;21(4):449-455.
24. Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AY. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta- analysis. Thromb Res. 2014;134(6):1214- 1219.
25. Lee AY, Levine MN, Baker RI, et al. Low- molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2): 146-153.
1442
haematologica | 2020; 105(5)